Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K/A on January 9, 2017, primarily to attach a press release dated January 8, 2017, which announced key business priorities for 2017. This press release also contained preliminary financial information, including revenue estimates, for the fourth quarter and full year ended December 31, 2016. Investors should note that the information provided in this press release is considered non-filed under Section 18 of the Securities Exchange Act, meaning it is not subject to the same legal liabilities. However, it offers a forward-looking view on the company's strategic direction and preliminary performance indicators for the recent fiscal year. Investors interested in Vertex's performance and strategic outlook for 2017 should review the attached press release for detailed insights into their business priorities and preliminary financial results.
Key Highlights
- 1Vertex Pharmaceuticals issued a press release on January 8, 2017, announcing 2017 business priorities.
- 2The press release included preliminary revenue and financial information for the fourth quarter and full year 2016.
- 3This 8-K/A filing serves to incorporate the January 8, 2017 press release as Exhibit 99.1.
- 4The provided financial information is preliminary and was issued before the finalization of the 2016 fiscal year results.
- 5Information furnished in the press release is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- 6This filing provides investors with an early look at Vertex's strategic focus for the upcoming year and initial performance indicators.